Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Morlat

Showing results (121-130 of 174) with videos related to

Pageof 18
Sort By:
La Revue De Medecine Interne|May 7, 2013
[100 essential drugs. An internal medicine approach]M Thomas, P Arlet, O Aumaitre, et al.
Annales De Medecine Interne|October 29, 1998
[Scleroderma renal crisis. 7 cases and review of the literature]F Bonnet, M Longy-Boursier, M Aparicio, et al.
Transfusion|January 1, 1989
Risk factors of HIV-seropositive subjects detected through blood donation in France, 1985-1988J J Lefrere, D Richard, A M Couroucé, et al.
The Journal of Infectious Diseases|July 29, 2000
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patientsJ M Molina, F Ferchal, C Rancinan, et al.
HIV Medicine|March 7, 2013
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptionsM Winnock, F Bani-Sadr, E Pambrun, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2003
Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control studyF Bonnet, M Bonarek, P Morlat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1991
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumorsS Roithmann, M Toledano, J M Tourani, et al.
Medecine Et Maladies Infectieuses|February 1, 2005
[Causes of death among HIV infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART)]C Lewden, M Sobesky, A Cabié, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupM Savès, F Raffi, P Clevenbergh, et al.
Journal of Viral Hepatitis|June 23, 2011
Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patientsM A Loko, F Bani-Sadr, M Winnock, et al.
Pageof 18

Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
La Revue De Medecine Interne|May 7, 2013
[100 essential drugs. An internal medicine approach]M Thomas, P Arlet, O Aumaitre, et al.
Annales De Medecine Interne|October 29, 1998
[Scleroderma renal crisis. 7 cases and review of the literature]F Bonnet, M Longy-Boursier, M Aparicio, et al.
Transfusion|January 1, 1989
Risk factors of HIV-seropositive subjects detected through blood donation in France, 1985-1988J J Lefrere, D Richard, A M Couroucé, et al.
The Journal of Infectious Diseases|July 29, 2000
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patientsJ M Molina, F Ferchal, C Rancinan, et al.
HIV Medicine|March 7, 2013
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptionsM Winnock, F Bani-Sadr, E Pambrun, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2003
Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control studyF Bonnet, M Bonarek, P Morlat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1991
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumorsS Roithmann, M Toledano, J M Tourani, et al.
Medecine Et Maladies Infectieuses|February 1, 2005
[Causes of death among HIV infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART)]C Lewden, M Sobesky, A Cabié, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupM Savès, F Raffi, P Clevenbergh, et al.
Journal of Viral Hepatitis|June 23, 2011
Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patientsM A Loko, F Bani-Sadr, M Winnock, et al.
Pageof 18